SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?


To: Mohan Marette who wrote (4706)6/23/1999 2:02:00 PM
From: jim kelley  Respond to of 12475
 
US farmers get pictures of their crop land from satellites images.
This is a natural application for Asia and India. Probably they should make this service available to farmers at a library so all farmers have access to it. They also need an imaging satellite hooked up to the web.

The same information distribution can be done with weather satellites in these countries. It would save lives, livestock and crops.

Regards,

Jim Kelley

P.S. Maybe DELL should offer services of this type free in Asia and India with its PC's. It is a lot easier to justify purchase of a PC
when it directly impacts family safety and farm production.



To: Mohan Marette who wrote (4706)6/23/1999 9:01:00 PM
From: Mohan Marette  Respond to of 12475
 
RPG Life Sciences is on the hunt-[RPG Group-The house of Goenkas]

House of Goenkas
rpgnet.com

RPG Group Website.
rpgnet.com

RPG Life Sciences is on the hunt for critical care brands

Sitaraman Shankar
MUMBAI 23 JUNE

RPG Life Sciences, the erstwhile Searle India, is on the look-out for brands in its new Critimed division. The board of the company has approved a proposal to finalise a deal which could involve, among others, a handful of brands being trawled by Mumbai-based merchant banker Lazard CreditCapital.

Sources said the company has decided to set aside a sum of Rs 5-10 crore for the acquisitions. An RPG group spokesman confirmed to the The Economic Times that RPG Life Sciences has been approached by Lazard, and said the acquisitions were aimed at attaining critical mass for Critimed.

The company is likely to buy as many as eight to ten medium-sized brands in the anti-cancer, cardiovascular and renal transplant areas.
The Critimed division is to be launched very soon, and the company is currently recruiting staff for the division. The new division is to focus on critical care, as opposed to Accumed, the acute medical care division which is already on the ground.

The spokesman said that in the renal area, RPG Life Science would look for a brand in its TRIT (triple regimen immunosuppressant therapy) area.

The company is looking for brands to market cyclosporins, as it already has the advantage of being a producer of the bulk drug. The largest cyclosporin brand is Novartis' Rs 10-crore Sandimmune. Cipla, Panacea, Criticare Ltd, Dabur and Indopharma also have cyclosporin brands.

RPG is also understood to be looking for a brand in methyl prednisolone, a product failure treatment. The largest brand in this segment is Pharmacia India's Solumedrol. Criticare also has a brand in this segment.

The third product in the TRIT basket is azatheoprine, in which RPG already has a Rs 3-crore brand, Azoran.

In the post-TRIT segment, there is a possibility of acquiring an amphotericin B brand for use in deep fungal infection. This brand, however, will go into the Accumed division of RPG Life Science and not Critimed.

In the anti-cancer segment, the company wants brands which use its bulk drugs vancomycin, dobutamine and doxorubicin.

Renal and anti-cancer segments alone account for Rs 85 crore sales as per retail audit, and the acquisitions will largely look to address these segments. The intensive care unit segment has sales of Rs 22 crore.

RPG Life Science's pharma business had sales of Rs 110 crore for the year ended March 1999. It has a field force of 300, and is appointing 15 highly trained sales staff, some of whom have medical qualifications, for the Critimed division. (Source:ET)